Home › Compare › MGCLF vs GBDC

MGCLF vs GBDC: Dividend Comparison 2026

MGCLF yields 747.66% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MGCLF wins by $1570975.36M in total portfolio value
10 years
MGCLF
MGCLF
● Live price
747.66%
Share price
$0.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1570996.21M
Annual income
$1,243,755,946,498.34
Full MGCLF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — MGCLF vs GBDC

📍 MGCLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMGCLFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MGCLF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MGCLF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MGCLF
Annual income on $10K today (after 15% tax)
$63,551.40/yr
After 10yr DRIP, annual income (after tax)
$1,057,192,554,523.59/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, MGCLF beats the other by $1,057,178,571,399.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MGCLF + GBDC for your $10,000?

MGCLF: 50%GBDC: 50%
100% GBDC50/50100% MGCLF
Portfolio after 10yr
$785508.53M
Annual income
$621,886,198,616.09/yr
Blended yield
79.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

MGCLF
No analyst data
Altman Z
-16.1
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MGCLF buys
0
GBDC buys
0
No recent congressional trades found for MGCLF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMGCLFGBDC
Forward yield747.66% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$1570996.21M ✓$20.85M
Annual income after 10y$1,243,755,946,498.34 ✓$16,450,733.83
Total dividends collected$1544814.76M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MGCLF vs GBDC ($10,000, DRIP)

YearMGCLF PortfolioMGCLF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$85,466$74,766.36$12,492$1,791.70+$73.0K → MGCLF
2$688,646$597,197.00$16,527$3,160.58+$672.1K → MGCLF
3$5,233,973$4,497,122.12$23,588$5,904.90+$5.21M → MGCLF
4$37,544,137$31,943,785.57$37,141$11,901.65+$37.51M → MGCLF
5$254,319,833$214,147,606.64$66,205$26,463.38+$254.25M → MGCLF
6$1,627,834,568$1,355,712,346.12$137,452$66,612.65+$1627.70M → MGCLF
7$9,851,651,442$8,109,868,455.03$342,372$195,298.53+$9851.31M → MGCLF
8$56,411,273,720$45,870,006,676.23$1,053,292$686,954.33+$56410.22M → MGCLF
9$305,832,024,786$245,471,961,906.33$4,111,439$2,984,416.95+$305827.91M → MGCLF
10$1,570,996,213,020$1,243,755,946,498.34$20,849,974$16,450,733.83+$1570975.36M → MGCLF

MGCLF vs GBDC: Complete Analysis 2026

MGCLF — Stock

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.

Full MGCLF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this MGCLF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MGCLF vs SCHDMGCLF vs JEPIMGCLF vs OMGCLF vs KOMGCLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.